Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001641172-25-004717
Filing Date
2025-04-15
Accepted
2025-04-15 09:15:28
Documents
19
Period of Report
2025-04-15

Document Format Files

Seq Description Document Type Size
1 formdef14a.htm   iXBRL DEF 14A 708894
2 chart_001.jpg GRAPHIC 53136
3 chart_002.jpg GRAPHIC 51761
4 proxy_001.jpg GRAPHIC 317493
5 proxy_002.jpg GRAPHIC 293548
  Complete submission text file 0001641172-25-004717.txt   3096372

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE envb-20241231.xsd EX-101.SCH 5337
7 XBRL DEFINITION FILE envb-20241231_def.xml EX-101.DEF 9643
8 XBRL LABEL FILE envb-20241231_lab.xml EX-101.LAB 62494
9 XBRL PRESENTATION FILE envb-20241231_pre.xml EX-101.PRE 44313
21 EXTRACTED XBRL INSTANCE DOCUMENT formdef14a_htm.xml XML 88294
Mailing Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103
Business Address 4851 TAMIAMI TRAIL N, SUITE 200 NAPLES FL 34103 239-302-1707
Enveric Biosciences, Inc. (Filer) CIK: 0000890821 (see all company filings)

EIN.: 954484725 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38286 | Film No.: 25837824
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)